Hyperthermia and Proton Therapy in Unresectable Soft Tissue Sarcoma (HYPROSAR)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by Kantonsspital Aarau
Sponsor:
Collaborators:
Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland
University Hospital, Zürich
Division of Radiation Oncology, University Hospital, Zurich, Switzerland
Information provided by (Responsible Party):
Prof. Dr. med. Niloy Ranjan Datta, Kantonsspital Aarau
ClinicalTrials.gov Identifier:
NCT01904565
First received: July 10, 2013
Last updated: March 11, 2014
Last verified: March 2014
  Purpose

This is a multi-institutional phase I/II clinical trial with concomitant local hyperthermia and proton beam radiotherapy in patients with primary or recurrent unresectable soft tissue sarcomas of the extremities, trunk, retroperitoneum (except intrabdominal). The primary purpose would be to assess the safety and efficacy of this approach along with local tumour regressions and subsequent tumour downstaging, thereby enabling a near total removal of these tumours following the hyperthermia and proton beam therapy.


Condition Intervention Phase
Soft Tissue Sarcoma
Radiation: Hyperthermia and Proton Beam
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Concurrent Hyperthermia and Proton Beam Radiotherapy in Primary and Recurrent Unresectable Soft Tissue Sarcoma

Resource links provided by NLM:


Further study details as provided by Kantonsspital Aarau:

Primary Outcome Measures:
  • To evaluate safety of hyperthermia and proton beam treatment in unresectable soft tissue sarcomas [ Time Frame: 6 months from end of treatment ] [ Designated as safety issue: Yes ]
    Acute and late morbidities of the treatment would be evaluated according to the CTCAE 4.0 guidelines during and until 6 months after the treatment


Secondary Outcome Measures:
  • To evaluate the local response to hyperthermia and proton beam therapy as a preoperative regimen for unresectable soft tissue sarcomaLocal control [ Time Frame: 6 months following the completion of study treatment ] [ Designated as safety issue: No ]
    Imaging response according to RECIST criteria comparing pretreatment MRI versus post treatment MRI taken 4 to 6 weeks after completion of the study treatment.


Other Outcome Measures:
  • Local disease free survival [ Time Frame: Would be assessed every 6 monthly up to a maximum of 48 months ] [ Designated as safety issue: No ]
    Local disease free survival would be computed using the Kaplan-Meir survival statistics


Estimated Enrollment: 26
Study Start Date: February 2014
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Thermoradiotherapy
Patients subjected to the planned therapeutic intervention of local hyperthermia and proton beam therapy
Radiation: Hyperthermia and Proton Beam
  1. Local hyperthermia,once a week for 5 to 7 weeks to a temperature of 41.5 to 42.5 degree Centigrade
  2. Proton beam therapy, 5 days a week at 1.8 - 2.0 GyE per fraction to a dose of 55 - 60 GyE (preoperative) or 72 - 76 GyE (for radical. Patients who have good response at 5 weeks of treatment would be considered for preoperative treatment, while those with unsatisfactory response that could be taken up for at least R0 resection would be treated to a radical dose.
Other Names:
  • 1. Local hyperthermia
  • 2. Proton beam therapy

Detailed Description:

Hyperthermia would be delivered at Kantonsspital Aarau (KSA) with superficial or deep hyperthermia treatment units as may be appropriate. All patients would undergo a pre-hyperthermia treatment planning and a temperature of around 41.5 Centigrade to 42.5 Centigrade would be aimed during hyperthermia sessions.Hyperthermia would be delivered once a week and the treatment sessions would last for around 60 minutes of active heating.

Proton bean therapy would be carried out at Center of Proton Therapy, Paul Scherrer Institute (PSI), Villigen using scanning beam proton therapy. A preoperative dose of 55 - 60 Gray equivalent (GyE) or those considered for radical treatment, 72-76 GyE would be delivered, 5 days a week at 1.8 - 2 Gy/fr.

On days of both hyperthermia at KSA and proton therapy at PSI, the time interval between the two treatments could be 90 to 150 minutes, taking into consideration the time to travel between the two institutions. Hyperthermia in these days would follow proton beam therapy.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histopathologically proven and classified soft tissue sarcoma (STS) as per the WHO classification (2002). For all primary tumours, biopsy would be done within 2 months prior to registration and reviewed by the study pathologist. For all recurrent tumours, if prior biopsy has been done elsewhere, the histopathology would be reviewed by the study pathologist.
  2. Primary STS of extremities, trunk (except intrabdominal) and retroperitoneal which are,

    1. Deemed inoperable by the study surgeon
    2. Not feasible for a limb sparing surgery with possible R0/R1 resection as per the study surgeon,
    3. Patient medically unfit to undergo surgery
    4. Patient refuses surgery
  3. Recurrent STS extremities and trunk would be eligible if

    1. Deemed inoperable by the study surgeon
    2. Not feasible for a limb sparing surgery with possible R0/R1 resection as per the study surgeon,
    3. Patient medically unfit to undergo surgery
    4. Patient refuses surgery
    5. Had not received prior radiotherapy to the proposed site of treatment.
  4. All patients having extremity STS with stages T2 and G2 or 3 with M0 (Stages IIB and III as per American Joint Committee on Cancer, AJCC 2010), would be included. For patients of STS of trunk, tumours less than 5cm may also be included if they are considered unresectable.
  5. Age more than 18 years
  6. Eastern Cooperative Oncology Group,ECOG performance scale 0 and 1
  7. Female patients must use effective contraception; must not be pregnant or lactating
  8. Life expectancy of atleast 2 years based on the age and co-morbidities, but excluding diagnosis of STS
  9. Absence of psychological, familial, sociological or geographical condition that could potentially hamper compliance with the study protocol and follow-up schedule
  10. Willing to travel to Paul Scherrer Institute for proton therapy and to Kantonsspital Aarau for Hyperthermia treatment.
  11. Agree to comply with the protocol
  12. Patients must sign a study specific informed consent form prior to registration.

Exclusion Criteria:

  1. Histopathology of rhabdomyosarcoma, extraosseous Ewing's, primary neuroectodermal tumour, aggressive fibromatosis (desmoids tumours), dermatofibrosarcoma protuberans, gastrointestinal stromal tumours, osteosarcoma, chondrosarcoma, Kaposi's sarcoma or angiosarcoma of scalp/face/neck
  2. Prior radiotherapy to the site of treatment
  3. Intrabdominal soft tissue sarcomas
  4. Use of neoadjuvant chemotherapy prior to radiotherapy or surgery
  5. Patients with regional nodal metastasis
  6. Patients with unequivocal distant metastasis
  7. No prior or concurrent malignancies other than surgically treated squamous cell or basal cell carcinoma of the skin which are not in the area of the present malignancy or in situ carcinoma of the skin
  8. No serious medical illness which would prevent informed consent or limit survival to less than 2 years
  9. Active uncontrolled bacterial, viral or fungal infections until these conditions are corrected or controlled.
  10. Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator would preclude the patient from meeting the study requirements.
  11. Patients having metal implants, pacemakers or clustered markers
  12. Patient who had a history of myocardial infarction within the past 12 months
  13. No connective disease disorders that contraindicate radiotherapy, e.g., Scleroderma

    -

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01904565

Contacts
Contact: Niloy R Datta, MD, DNB, +41-62 8389559 niloyranjan.datta@ksa.ch
Contact: Stephan Bodis, MD +41-62 838 5371 stephan.bodis@ksa.ch

Locations
Switzerland
Kantonsspital Aarau Recruiting
Aarau, Aargau, Switzerland, CH 5001
Contact: Niloy R Datta, MD, DNB, CCST    0041 62 8389559    niloyranjan.datta@ksa.ch   
Contact: Emsad Puric, MD    0041 92 85385    Emsad.Puric@ksa.ch   
Principal Investigator: Niloy R Datta, MD, DNB         
Sponsors and Collaborators
Kantonsspital Aarau
Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland
University Hospital, Zürich
Division of Radiation Oncology, University Hospital, Zurich, Switzerland
Investigators
Principal Investigator: Niloy R Datta, MD, DNB Kantonsspital Aarau, Switzerland
  More Information

Additional Information:
No publications provided

Responsible Party: Prof. Dr. med. Niloy Ranjan Datta, Senior Consultant, Department of Radiation Oncology, KSA, Kantonsspital Aarau
ClinicalTrials.gov Identifier: NCT01904565     History of Changes
Other Study ID Numbers: KSA_HYPROSAR1
Study First Received: July 10, 2013
Last Updated: March 11, 2014
Health Authority: Switzerland: Ethikkommission

Keywords provided by Kantonsspital Aarau:
Hyperthermia,
Proton beam therapy
Soft Tissue Sarcoma
Radiotherapy
Phase I/II trial

Additional relevant MeSH terms:
Fever
Sarcoma
Body Temperature Changes
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Signs and Symptoms

ClinicalTrials.gov processed this record on October 29, 2014